CONFIDENTIAL

Gene-Specific COLARIS®
PMS2 Analysis Result

PHYSICIAN	SPECIMEN	PATIENT
John Smith, MD **Comprehensive Medical Center** **1100 Grand Ave** **Away, GA 12345**	Specimen: **Blood** Draw date: **Aug 01, 2010** Accession date: **Aug 02, 2010** Report Date: **Aug 12, 2010**	Name: **Doe, Jane** Date of Birth: **April 1, 1492** Patient ID: **000000** Gender: **Female** Accession #: **00000000-BLD** Requisition #: **000000**

Test Results and Interpretation

NO MUTATION DETECTED

Test Performed:	Result:	Interpretation:
PMS2 sequencing	No Mutation Detected	No Mutation Detected
rearrangement analysis	No Mutation Detected	No Mutation Detected

Analysis consists of sequencing of all exons and adjacent intronic regions of the PMS2 gene and rearrangement testing of the PMS2 gene by multiplex ligation-dependent probe amplification (MLPA). The MLPA reagents used for this analysis have not been approved or cleared by the FDA. However, Myriad Genetic Laboratories, Inc. has validated the performance characteristics of this test. Additionally, please note that rare interfering variants may exist which could lead to false positive or negative results. The classification and interpretation of all variants identified in this assay reflect the current state of scientific understanding at the time this report was issued. In some instances, the classification and interpretation of such variants may change as new scientific information becomes available.

It is our understanding that this patient was identified for testing due to a personal or family history suggestive of Lynch syndrome (hereditary non-polyposis colorectal cancer, HNPCC). No deleterious mutation was found in PMS2 in this individual by full sequence and MLPA analysis. Sequence analysis identifies mutations in all 15 exons and approximately 450 non-coding base pairs of PMS2. MLPA analysis identifies duplications and deletions involving one or more exons of PMS2. There are rare genetic abnormalities in PMS2 that this test will not detect. Testing of MLH1, MSH2 and MSH6 may be appropriate if not already performed. This result by itself therefore does not exclude the possibility of Lynch syndrome.

Please contact Myriad Professional Support at 1-800-469-7423 to discuss any questions regarding this result.

Director Name Here
Qualifications Here

Director Name Here
Qualifications Here

These test results should only be used in conjunction with the patient's clinical history and any previous analysis of appropriate family members. It is strongly recommended that these test results be communicated to the patient in a setting that includes appropriate counseling. The accompanying Technical Specifications summary describes the analysis, method, performance characteristics, nomenclature, and interpretive criteria of this test. This test may be considered investigational by some states. This test and its performance characteristics were determined by Myriad Genetic Laboratories. It has not been reviewed by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary.